- Home
- GOSS vs ALPS Comparison
GOSS vs ALPS Comparison
Compare GOSS & ALPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GOSS | ALPS |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.8M | 66.6M |
| IPO Year | 2018 | 2024 |
Fundamental Metrics
Financial Performance| Metric | GOSS | ALPS |
|---|---|---|
| Price | $9.32 | $0.34 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $95.40 | N/A |
| AVG Volume (30 Days) | ★ 289.5K | 46.8K |
| Earning Date | 11-04-2026 | 07-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.11 | $0.23 |
| 52 Week High | $12.52 | $1.72 |
Technical Indicators
Market Signals| Indicator | GOSS | ALPS |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 35.77 |
| Support Level | $0.18 | $0.23 |
| Resistance Level | $12.49 | $0.44 |
| Average True Range (ATR) | 0.84 | 0.02 |
| MACD | -0.58 | -0.01 |
| Stochastic Oscillator | 10.66 | 14.87 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
About ALPS ALPS Group Inc Ordinary Share
ALPS Group Inc is an investment holding company involved in research and development, including stem cell and biotechnology-related business, and investing and managing businesses such as health and beauty centres and medical centres. The Company operates through Medical and Wellness, Life Science and Others segments. Medical and Wellness generates maximum revenue from non-surgical aesthetic services, surgical aesthetic services, medical consultation, health screenings, cellular therapy and research, and COVID-19 testing. Life Science provides whole-genome sequencing and pharmacogenomics, while Others comprises investment holding and provision of management services. The Company generates revenue in Malaysia.